



Contact:

Justyna Gudaszevska

Crescendo Communications Europe Sp. z o.o.

Email: mmd@crescendo-ir.com

Tel: + 48 71 79 11 551

Milestone Medical Inc. Provides Update on U.S. Clinical Trials for Epidural Instrument

Milestone Medical has commenced pivotal IDE clinical trial in the U.S. with the aim of confirming epidural space location

Three prominent university and pain management sites in the United States have received Institutional Review Board approvals

Pivotal clinical trial reaches important milestone of 100 patients enrolled

LIVINGSTON, NJ, April 22, 2015 -- Milestone Medical Inc. (WAR: MMD), today provided an update on its previously announced pivotal Investigational Device Exemption (IDE) clinical trial in the U.S. whose aim is to verify the placement of the epidural needle tip in the lumbar epidural space. The company has also disclosed that three prominent university and pain management sites in the United States have received Ethical Committee (Institutional Review Board) approvals which enable the initiation of site enrollment. The clinical trial for the company's epidural instrument has reached an enrollment of 100 patients. The goal of the pivotal IDE clinical trial is to demonstrate the safety and efficacy of the epidural instrument.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "With Milestone Medical receiving clinical trial registration approval from the FDA just over a month ago, we are pleased with the rate of enrollment in this relatively short time. Milestone Medical plans to enroll up to 400 patients in the trial at four separate sites in the U.S. Upon achieving full enrollment, we expect the clinical trial and accompanying statistical analysis to be completed in the third quarter of 2015, at which time Milestone Medical will return to the FDA for final market clearance. With the U.S. epidural market estimated at over \$7 billion annually and over 2.4 million women receiving epidurals, we believe this instrument will help reduce health risks to patients and malpractice risk to medical professionals administering epidurals."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular

instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and China and has recently received CE approval for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###